Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 19;23(9):4501.
doi: 10.3390/ijms23094501.

Resolution of Inflammation in Retinal Disorders: Briefly the State

Maria Consiglia Trotta  1 , Carlo Gesualdo  2 , Francesco Petrillo  1 , Caterina Claudia Lepre  1 , Alberto Della Corte  2 , Giancuomo Cavasso  2 , Giulia Maggiore  3 , Anca Hermenean  4 , Francesca Simonelli  2 , Michele D'Amico  1 , Settimio Rossi  2
Affiliations
Review

Resolution of Inflammation in Retinal Disorders: Briefly the State

Maria Consiglia Trotta et al. Int J Mol Sci. .

Abstract

The most frequent retinal diseases, such as diabetic retinopathy, age-related macular degeneration and posterior uveitis, are underlined by oxidative stress or aging-induced retinal inflammation, which contributes to vision impairing or loss. Resolution of inflammation is emerging as a critical phase able to counteract the inflammatory process leading to the progression of retinal damage. Particularly, pro-resolving mediators (PMs) play a key role in the modulation of inflammatory exudates and could be considered a new target to be investigated in different inflammatory-autoimmune pathologies. Here, we highlight the most recent studies concerning the role of the main PMs (lipoxins, resolvins, prtectins, maresins and annexins) in retinal inflammation, in order to collect the best evidence in the field of inflammatory retinal damage resolution and to propose novel pharmacological approaches in the management of the most common retinal diseases.

Keywords: annexins; galectins; inflammation; lipoxins; maresins; pro-resolving mediators; protectins; resolvins; retinopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Main lipidic PMs: precursors and biosynthesis enzymes. LOX: lipoxygenase; COX: cyclooxygenase.
Figure 2
Figure 2
Annexins categories and their expression in different phyla.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Xu H., Rao N.A. Grand Challenges in Ocular Inflammatory Diseases. Front. Ophthalmol. 2022;2:756689. doi: 10.3389/fopht.2022.756689. - DOI - PMC - PubMed
    1. Gesualdo C., Balta C., Platania C.B.M., Trotta M.C., Herman H., Gharbia S., Rosu M., Petrillo F., Giunta S., Della Corte A., et al. Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Front. Pharmacol. 2021;12:718902. doi: 10.3389/fphar.2021.718902. - DOI - PMC - PubMed
    1. Whitcup S.M., Nussenblatt R.B., Lightman S.L., Hollander D.A. Inflammation in Retinal Disease. Int. J. Inflamm. 2013;2013:724648. doi: 10.1155/2013/724648. - DOI - PMC - PubMed
    1. Roy S., Amin S., Roy S. Retinal Fibrosis in Diabetic Retinopathy. Exp. Eye Res. 2016;142:71–75. doi: 10.1016/j.exer.2015.04.004. - DOI - PMC - PubMed
    1. Burns R.P., Feeney-Burns L. Clinico-Morphologic Correlations of Drusen of Bruch’s Membrane. Trans. Am. Ophthalmol. Soc. 1980;78:206–225. - PMC - PubMed